Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system

Abstract This study aimed to empirically analyze gastrointestinal adverse events associated with Lenvatinib monotherapy and its combination with Pembrolizumab using FDA FAERS data (January 2015-December 2023), focusing on risk profiles, temporal patterns, and influencing factors. Proportional dispro...

Full description

Saved in:
Bibliographic Details
Main Authors: Chufeng Ding, Lin Ma, Yankun Liang, Zhenpo Zhang, Qimin Wu, Jun Lyu, Ling Su
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Lenvatinib
Lenvatinib plus Pembrolizumab
Data mining
FAERS
Gastrointestinal adverse events
Online Access:https://doi.org/10.1038/s41598-025-99773-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-99773-4

Similar Items